HNB
IMUC

Huntington National Bank’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Huntington National Bank’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-69
Closed – – 1671
2016
Q2 		$0 Buy
+69
New +$710 ﹤0.01% 1913

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Huntington National Bank's IMUC Position: Q3 2016 in Review

Huntington National Bank sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2016, closing a stake of 69 shares.

Huntington National Bank first reported a position in IMUC in Q2 2016 and held it in 1 quarter. The position peaked at $0 in Q2 2016. 31 funds tracked by Wall St. Rank hold IMUC as of Q3 2016.

  • Huntington National Bank reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2016 after selling out during the quarter.
  • Huntington National Bank sold 69 ImmunoCellular Therapeutics, Ltd. shares in Q3 2016.
  • Huntington National Bank first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2016 and held it in 1 quarter.
  • Huntington National Bank's ImmunoCellular Therapeutics, Ltd. position peaked at $0 in Q2 2016.
  • 31 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2016.

Based on Huntington National Bank's 13F filing for Q3 2016, filed 31 Oct 2016.